Bismarck News Updates

Imagine that Cost effective personalized medicine be possible for Heart Failure

 Breaking News
  • No posts were found

Imagine that Cost effective personalized medicine be possible for Heart Failure

June 05
11:09 2020
• InvivoSciences Inc. Selected as Finalist for MassChallenge Boston 2020 Accelerator

• InvivoSciences, Inc. joins the global network of Startups

Madison, WI – June 4th, 2020 – Yesterday, InviviSciences, Inc., is a small biotech company selected to participate in the Boston 2020 accelerator program. InvivoSciences, Inc. was one of over 1100 other startups to apply for the accelerator located in Boston. 

Ayla Annac, a CEO/president of InvivoSciences, Inc., said, “Our team and co-founder, board and stakeholders are super excited to participate Boston 2020 accelerator program as a finalist and access to the experts, resources, potential partners and funding opportunities”. We are honored to be part of this amazing ecosystem of entrepreneurs, judges, experts, and global leaders committed to creating a future of our economies and industries, jobs, human health, and ecosystems. 

We believe both Mass Challenge enables us to reach out to new strategic partners to achieve our global commercialization goal that aims to reduce global deaths related to heart failure, which is the number reason for deaths in the USA and the world. InvivoSciences has scalable technologies that deliver high cost and time savings to the pharmaceutical industry to reduce animal testing, and potentially lead to safer & more effective human clinical trials. Animal disease models have shortcomings. More than 90% of drugs fail in early human testing because safety and efficacy results from animal tests do not always predict drug performance in humans. Our NuHeart™, micro heart-tissues are derived from healthy and patient-derived induced pluripotent stem cells. Its ready-to-use automated assay platform will redefine the preclinical landscape by introducing patient-relevant samples for early-stage heart failure studies. The NuHeart™ is personalizing heart failure drug development by focusing on a specific patient group to reduce the size of clinical trials.

As the flagship program, the MassChallenge Boston accelerator supports more than 100 startups across industries and from regions around the world. Acceptance into the competitive program offers unmatched access to top experts, corporate partners, evidence-backed programming, and more. At its culmination in October, top startups have a unique opportunity to compete for up to $1M in cash prizes at the annual MassChallenge Awards. 

InvivoScience, Inc. (IVS), is a Madison, Wisconsin based private life science company that has developed the next-generation, best-in-class, human-tissue based system for predictive drug development. The platform is fully functional, scalable, and automated to deliver repeatable and reliable results. It is also ideal for disease modeling and enables a powerful capability to predict the human response of the myocardium to a treatment – thus bringing tremendous value to pharmaceutical developers who are evaluating the safety, toxicity, and efficacy of new drug candidates before investing significant resources in human trials.  As such, the technology can dramatically help mitigate the historically high risk of clinical trial failure because of the potentially lethal effects of heart failure due to drug-induced cardio-toxicity. We aim to reduce deaths due to heart failure worldwide and put our energies with partners to help develop cost-effective precision medicine for heart failure using the systems and lead product NuHeart™, Currently, IVS has developed robust capabilities of its platform for screening new drugs for cardiotoxicity risk with a focus on therapeutics in cancer and rare or neglected disease areas.

For more information, visit: www.invivosciences.com

About MassChallenge 

MassChallenge is a global network of zero-equity startup accelerators. Headquartered in the United States with locations in Boston, Israel, Mexico, Switzerland, Texas, and the UK, MassChallenge is committed to strengthening the global innovation ecosystem by supporting high-potential early-stage startups across all industries, from anywhere in the world. To date, more than 2,400 MassChallenge alumni have raised more than $6.2 billion in funding, generated over $3 billion in revenue, and created over 157,000 total jobs.

Learn more about MassChallenge at masschallenge.org

Media Contact
Company Name: InvivoSciences Inc.
City: Madison
State: WI
Country: United States
Website: https://www.invivosciences.com